View Risk


Article data
Ji (2020)
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study
https://doi.org/10.1016/j.jhep.2020.03.044
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141624/

Results
Comorbidities
Any comorbidity (Present vs. Not present)
COVID-19 (severe/fatal)
Odds ratio: 6.300 (2.300-18.800) Adjusted model

Study characteristics

China

Retrospective cohort study

Medical records

202

From January 20 through February 17, 2020, consecutive patients admitted to 2 designated COVID-19 Hospitals in China with confirmed COVID-19 and information on NAFLD status were studied.

Two hundred and two consecutive patients with confirmed COVID-19 and information relating to NAFLD status were studied. Male sex (n,%) 113 (55.9); Age (years) 44.5 (34.8–54.1); Age >60 years (n, %) 31 (15.3) Liver injury was observed in 101 (50%) and 152 (75.2%) patients on admission and during hospitalization, respectively. Almost all liver injury was mild with hepatocellular pattern, only 2.6% (4/152) had ductular or mixed pattern. Sixty-seven (33.2%) patients had persistent abnormal liver function from admission to last follow-up. Thirty-nine (19.3%) and 163 (80.7%) had progressive and stable disease, respectively.

0


Results

COVID-19 (severe/fatal)

39

Progression of illness was defined as development of at least one of the following: respiratory rate >=30 breaths/min, resting oxygen saturation <=93% and PaO2/FiO2 <=300 mmHg or worsening of lung CT findings, during the hospitalization period.

Comorbidities

Any comorbidity

Underlying diseases. Comorbidity included hypertension, diabetes, cardiovascular disease, chronic lung disease and HIV infections.

Not present

Present

Odds ratio

6.300 (2.300-18.800)

No

Yes

Yes

Age, Gender, BMI, Comorbidity ( hypertension, diabetes, cardiovascular disease, chronic lung disease and HIV infections) and Non-Alcoholic Fatty Liver Diseases (NAFLD)


Other information

none

Average

Yes

Go Back